John P. O’Donnell

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases · 2023 · 286 citations

Pharmacy, Infectious Diseases, Pharmacology +14

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 271 citations

Life Sciences, Infectious Diseases, Microbiology +16

Contribution by purines to the neurogenic response of the vas deferens of the guinea pig

Jeffrey S. Fedan, G. Kurt Hogaboom, John P. O’Donnell et al. · European Journal of Pharmacology · 1981 · 240 citations

Life Sciences, Neuroscience, Physiology +9

Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrheae</i>, Including Multi-Drug-Resistant Isolates

Patricia A. Bradford, Alita A. Miller, John P. O’Donnell et al. · ACS Infectious Diseases · 2020 · 145 citations · Full text

Medicine, Infectious Diseases, Pharmacology +11

Rational design of a new antibiotic class for drug-resistant infections

Thomas F. Durand-Réville, Alita A. Miller, John P. O’Donnell et al. · Nature · 2021 · 140 citations

Life Sciences, Infectious Diseases, Medicinal Chemistry +16